Get started
Author

Daniela Delbeau-Zagelbaum

Observed name: Daniela Delbeau
Observed institutions: Memorial Sloan Kettering Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Tisch Cancer Institute, New York University, Icahn School of Medicine at Mount Sinai
ORCID: 0009-0004-5304-6042
Observed ORCID: 0009-0004-5304-6042
OpenAlex ID: A5114412159
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
2018 · Gopa Iyer, Arjun V. Balar, et al. · Journal of Clinical Oncology · 140
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025 · Mansi Saxena, Thomas U. Marron, et al. · Cancer Discovery · 28
Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC).
2016 · Arjun Vasant Balar, Gopa Iyer, et al. · Journal of Clinical Oncology · 7
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome
2025 · Cansu Cimen Bozkus, Matthew Brown, et al. · iScience · 6
PDF
Abstract CT270: Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting
2023 · Mansi Saxena, Thomas Marron, et al. · Cancer Research · 5
Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience
2019 · Miles M. Hsu, Yuhe Xia, et al. · Clinical Genitourinary Cancer · 4
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025 · Mansi Saxena, Thomas U. Marron, et al. · 1
PDF
289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting
2020 · Thomas Marron, Julia Kodysh, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2026 · Mansi Saxena, Thomas U. Marron, et al.
Abstract LB-B009: Design and immunogenicity of sequential cancer vaccination targeting shared tumor-associated antigens and personalized neoantigens in a single patient with uterine leiomyosarcoma
2026 · Mansi Saxena, Cansu Cimen Bozkus, et al. · Cancer Immunology Research
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025 · Mansi Saxena, Thomas U. Marron, et al.
PDF
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025 · Mansi Saxena, Thomas U. Marron, et al.
PDF
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025 · Mansi Saxena, Thomas U. Marron, et al.
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025 · Mansi Saxena, Thomas U. Marron, et al.
PDF
Works count: 33
Citation count: 192
H-index: 5
I10-index: 2
Year
Topic
Type